Clinical trials: Alcohol Liver Disease
Alcoholic Hepatitis
Treatment of Alcohol-Related Hepatitis With Arginine
The purpose of this study is to test the effectiveness of the amino acid arginine in reducing liver injury in individuals with alcohol-related hepatitis.
- Trial name
- NCT00200746
- Testing
- Arginine
- Where
- United States
- Sponsor
- National Center for Complementary and Integrative Health (NCCIH)
All Cause Mortality, Cardiovascular Diseases
Advice of Moderate Drinking Pattern Versus Advice on Abstention on Major Disease and Mortality
The goal of this clinical trial is to test two advices on alcohol drinking in more than 10.000 Spanish adult drinkers (men of 50 or more years and women of 55 or more years).
- Conditions
- All Cause Mortality, Cardiovascular Diseases, Invasive Cancer, Liver Cirrhosis
- Trial name
- UNATI (NCT06338215)
- Testing
- Moderate Alcohol Drinking Pattern, Abstention
- Where
- Spain
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- Clinica Universidad de Navarra, Universidad de Navarra
Liver Cirrhosis, Alcoholic, Progression
Prospective Cohort Study of Disease and Outcomes in Cirrhosis
A population based incidence cohort will enroll patients newly diagnosed with cirrhosis to investigate disease characteristics and outcomes, explore mechanisms predicting early death and hospital admission, and assess new…
- Conditions
- Liver Cirrhosis, Alcoholic, Progression, Liver Diseases, Decompensated Cirrhosis
- Trial name
- ProDoc (NCT04422223)
- Where
- Denmark
- Volunteers
- 550 people
- Sponsor
- Copenhagen University Hospital, Hvidovre
NAFLD, Diabetes Mellitus, Type 2
Study of ISIS 703802 in Participants With Hypertriglyceridemia, Type 2 Diabetes Mellitus, and Nonalcoholic Fatty Liver Disease
This is a multicenter, randomized, double-blind, placebo-controlled, dose-ranging study to evaluate the safety, including tolerability, of ISIS 703802 and to assess the efficacy of different doses and dosing regimens of ISIS…
- Conditions
- NAFLD, Diabetes Mellitus, Type 2, Hypertriglyceridemia, Fatty Liver, Nonalcoholic
- Trial name
- NCT03371355
- Testing
- ISIS 703802 40 mg, ISIS 703802 80 mg, ISIS 703802 20 mg
- Where
- 42 sites in United States, Canada
- Volunteers
- 105 people
- Sponsor
- Akcea Therapeutics
Liver Diseases, Alcoholic
A Study to Investigate the Safety and Efficacy of Efimosfermin Alfa Compared With Placebo in Adult Participants With Alcohol-related Liver Disease (ALD)
This is a dose-ranging study to evaluate safety of efimosfermin alfa and to establish proof-of-concept that efimosfermin alfa therapy provides benefit in participants with ALD.
- Trial name
- ALLSTAR (NCT07791043)
- Testing
- Efimosfermin alfa
- Where
- 4 sites in United States, Argentina
- Volunteers
- 274 people
- Sponsor
- GlaxoSmithKline
Hepatitis C, Substance Abuse
Psychoeducation for Hepatitis and Alcohol Behaviors
The proposed project will apply a unique, effective family-responsive psychoeducation program, PsychoEducation Responsive to Families (PERF), for Hepatitis C Virus (HCV) treatment.
- Trial name
- NCT00598416
- Testing
- Family-Responsive Psychoeducation Program (PERF)
- Where
- United States
- Volunteers
- 556 people
- Sponsor
- National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Cirrhosis, Cirrhosis, Liver
Liver Cirrhosis Network Cohort Study
Liver Cirrhosis Network (LCN) Cohort Study is an observational study designed to identify risk factors and develop prediction models for risk of decompensation in adults with liver cirrhosis.
- Conditions
- Cirrhosis, Cirrhosis, Liver, Cirrhosis Early, Cirrhosis Due to Hepatitis B
- Trial name
- LCN-C (NCT05740358)
- Where
- 14 sites in United States
- Volunteers
- 1,222 people
- Sponsor
- Northwestern University
Drug Induced Liver Injury
Acetaminophen Adduct Formation in Non-Drinkers Taking Therapeutic Doses of Acetaminophen for Ten Consecutive Days
Acetaminophen is commonly used to treat fever or pain. Your body clears acetaminophen by processing it in the liver. During the processing, some of the acetaminophen may bind to proteins in the liver.
- Trial name
- Non-Drinker (NCT00616018)
- Testing
- acetaminophen
- Where
- United States
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Kennon Heard
Hepatitis, Alcoholic
Alcoholic Hepatitis in Latin-America: A Prospective and Multicentric Study (AH-LATIN).
The primary objective of this study is to determine the prevalence of AH in addition to its clinical characteristics and in-hospital mortality of patients that are hospitalized for AH in different hospitals across Latin American…
- Trial name
- NCT04142723
- Testing
- blood withdraw
- Where
- Chile
- Volunteers
- 1,000 people
- Sponsor
- Pontificia Universidad Catolica de Chile
Alcoholic Liver Diseases
S-adenosylmethionine Plus Choline in Treatment of Patients With Alcoholic Liver Disease
The study will assess the effect of treatment with formulation containing S-Adenosyl methionine and choline, on patients with alcoholic liver disease.
- Trial name
- NCT03938662
- Testing
- formulation containing S-Adenosyl methionine and choline
- Where
- Serbia
- Volunteers
- 44 people
- Sponsor
- University Clinic Dr Dragisa Misovic-Dedinje
Non-alcoholic Fatty Liver Disease (NAFLD), Alcoholic Liver Disease (ALD)
Screening in Primary Care of Advanced Liver Fibrosis in NAFLD and/or Alcoholic Patients
The primary objective of the SOPRANO study is to compare two blood fibrosis tests, the eLIFT and the FibroMeter, for the screening of advanced liver fibrosis in patients with NAFLD and/or ALD from primary care centers.
- Conditions
- Non-alcoholic Fatty Liver Disease (NAFLD), Alcoholic Liver Disease (ALD), Liver Fibrosis
- Trial name
- SOPRANO (NCT05699018)
- Testing
- eLIFT
- Where
- 13 sites in France
- Volunteers
- 1,788 people
- Sponsor
- University Hospital, Angers
Alcohol-related Liver Disease
Contingency Management to Incentivise Treatment Adherence in Alcohol-related Liver Disease
A sample of 30 alcohol-related liver disease patients will be recruited through consecutive sampling, facilitated through the Alcohol Care Team, which will identify potential participants to the study that have been referred to…
- Trial name
- NCT06183710
- Testing
- Contingency management
- Where
- United Kingdom
- Volunteers
- 30 people
- Sponsor
- King's College Hospital NHS Trust
Alcohol-related Liver Disease
Acamprosate Safe to Use in Individuals With Liver Disease.
Is acamprosate safe to use in individuals with liver disease.
- Trial name
- NCT04287920
- Testing
- Acomprosate
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Mayo Clinic
Liver Transplant Recipient, Alcohol Use Disorders (AUD)
Intervention for Alcohol Use Disorder Recovery After Liver Transplantation
The goal of this clinical trial is to learn if it is feasible and acceptable to use a recovery coach and an online sober active community to help with alcohol use disorder after liver transplant.
- Trial name
- ILTARP (NCT07214259)
- Testing
- Online Sober Active Community, Recovery coach
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Leigh Anne Dageforde
Alcoholic Hepatitis
DUR-928 in Patients With Alcoholic Hepatitis
The proposed study is An Open-Label, Dose Escalation Study to Assess the Safety, and Pharmacodynamics (PD) signals of DUR 928 in Patients with AH.
- Trial name
- DUR-928/AH (NCT03917407)
- Testing
- DUR-928 (Moderate AH), DUR-928 (Severe AH)
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- Craig James McClain
Alcoholic Liver Disease
Stratification of Chronic Alcoholic Liver Diseases (SCALE Study)
Recent years, the European Association for the Study of the Liver-chronic liver failure (EASL-CLIF) has defined and graded acute-on-chronic liver failure (ACLF) based on CANONIC study which enrolled cirrhotic patients with acute…
- Trial name
- SCALE (NCT03295812)
- Testing
- standard therapy
- Where
- 26 sites in China
- Volunteers
- 3,000 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Alcoholic Hepatitis
Alcoholic Hepatitis Network Observational Study
The purpose of this research study is to create a clinical database and bio-repository. To do this, we will obtain blood, urine, saliva, and stool samples (e.g., biological samples) and personal health information from you to use…
- Trial name
- NCT03850899
- Where
- 9 sites in United States
- Volunteers
- 1,133 people, healthy volunteers welcome
- Sponsor
- Indiana University
Liver Failure, Hepatitis B
RCT Study on Granulocyte Colony-stimulating Factor(G-CSF) Treatment of Hepatic Failure
This study evaluates the Granulocyte colony-stimulating factor (G-CSF) in the treatment of Acute on Chronic Liver Failure in adult.
- Conditions
- Liver Failure, Hepatitis B, Alcoholic Liver Disease
- Trial name
- NCT02331745
- Testing
- Granulocyte colony-stimulating factor, standard treatment
- Where
- China
- Volunteers
- 140 people
- Sponsor
- Beijing 302 Hospital
Non-Alcoholic Fatty Liver Disease, Non-alcoholic Steatohepatitis
Integrated Diagnostics for Early Diagnosis of Liver Disease
This is an observational study that will explore the hypothesis that by combining data from patients with liver disease with novel blood biomarkers, single nucleotide polymorphism (SNP) analysis and faecal microbiome analysis.
- Conditions
- Non-Alcoholic Fatty Liver Disease, Non-alcoholic Steatohepatitis, Alcoholic Liver Disease, Liver Fibroses
- Trial name
- ID LIVER (NCT04666402)
- Testing
- Blood tests for Single Nucleotide Polymorphisms, Faecal microbiome analysis, Serum for diagnostic biomarkers
- Where
- United Kingdom
- Volunteers
- 1,200 people
- Sponsor
- Manchester University NHS Foundation Trust
Acute Alcoholic Hepatitis
Assess Safety and Efficacy of ELAD (Extracorporeal Liver Assist System) in Subjects With Alcohol-Induced Liver Failure
The primary objective of the study is to evaluate safety and efficacy of ELAD® with respect to overall survival (OS) of subjects with a clinical diagnosis of alcohol-induced liver decompensation (AILD) up to at least Study Day…
- Trial name
- NCT01471028
- Testing
- ELAD treatment, Standard of care (Control)
- Where
- 45 sites in United States, Australia and 2 more
- Volunteers
- 203 people
- Sponsor
- Vital Therapies, Inc.